Clinical Heterogeneity and Treatment in Anti-KLHL11 Encephalitis: Two Case Reports

Two case reports detail the clinical features and treatment responses of patients with anti-Kelch-like protein 11 (KLHL11) antibody-associated encephalitis. The data includes patient ages, antibody titers, treatment regimens, and outcomes. The document was authored by Lin Han and last updated on June 1, 2026.

Use Cases

• Analyze clinical heterogeneity in autoimmune encephalitis based on patient age, symptom presentation, and antibody titer.
• Compare treatment efficacy for anti-KLHL11 encephalitis based on regimens like intravenous immunoglobulin, rituximab, and efgartigimod.
• Investigate associations between serum antibody titers and treatment refractoriness based on the preliminary observation of a high titer (1:320).
• Study potential paraneoplastic origins based on findings like a testicular ultrasound revealing an epididymal calcification.

Strengths

• Includes detailed clinical data for two patients, including specific ages (52 and 65), antibody titers (1:100, 1:320), and precise treatment dosages.
• Provides a literature review of cases published in the last six years, offering broader context.
• The document is licensed under CC-BY-4.0, allowing for reuse with attribution.

Limitations

• The dataset is a single 781.0 KB PDF file; the underlying structured data is not provided.
• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred from the text.

Provenance

Source

figshare

Collection Method

Case report and literature review.

Freshness

Last updated 2026-06-01 05:18:33; freshness should be verified.